Citi analyst Geoff Meacham raised the firm’s price target on Regeneron (REGN) to $660 from $650 and keeps a Buy rating on the shares. The firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of a Q3 earnings preview. The group is well positioned into the second half of 2025 and 2026 as policy overhangs ease and investor focus returns to fundamentals, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces updated data for DB-OTO due to OTOF gene
- Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
- Regeneron Completes Study on Aflibercept’s Safety in Real-World Settings
- Regeneron’s Odronextamab Study Update: A Potential Game-Changer in B-Cell Malignancies
- Regeneron price target lowered to $756 from $761 at Morgan Stanley